Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Nov 2022
Cost of life-saving heart disease drugs slashed, saving patients thousands
27 November 2022 - Life-saving medicines that tackle Australia's biggest killer are about to be added to the Pharmaceutical Benefits ...
Posted by Michael Wonder on 27 Nov 2022
The cruellest tax: clipping the ticket on unfunded cancer drugs
28 November 2022 - Jo McKenzie-McLean’s life was turned upside down after a stage 4 bowel cancer diagnosis. ...
Posted by Michael Wonder on 26 Nov 2022
GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review
25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against ...
Posted by Michael Wonder on 25 Nov 2022
Taiho Pharmaceutical obtains additional indication of "post-operative adjuvant chemotherapy for hormone receptor positive and HER2 negative breast cancer at high risk of recurrence" for oral anti-cancer agent TS-1
24 November 2022 - Based on POTENT study results. ...
Posted by Michael Wonder on 25 Nov 2022
Spectrum Pharmaceuticals receives complete response letter from US Food and Drug Administration for poziotinib
25 November 2022 - Spectrum Pharmaceuticals today announced that the Company has received a complete response letter from the US FDA ...
Posted by Michael Wonder on 25 Nov 2022
Hugel's 'Letybo' first in Korea to obtain marketing approval from Australia
24 November 2022 - Obtained marketing approval on the 23rd (local time) from the TGA of Australia for the indication of ...
Posted by Michael Wonder on 25 Nov 2022
Junshi Biosciences announces submission of a marketing authorisation application for toripalimab to the UK MHRA
24 November 2022 - Second marketing authorisation application submission in Europe reflects toripalimab’s steady yet speedy progress towards global commercialisation. ...
Posted by Michael Wonder on 25 Nov 2022
Health Canada authorises Polivy (polatuzumab vedotin) for the first-line treatment of adults with large B-cell lymphoma
24 November 2022 - Authorization is based on pivotal data from the Phase 3 POLARIX trial, which met its primary ...
Posted by Michael Wonder on 24 Nov 2022
GPs can't prescribe ADHD medication, some say that's a problem
24 November 2022 - When Ben Mitchell was first diagnosed with attention deficit hyperactivity disorder (ADHD), he waited four months to ...
Posted by Michael Wonder on 24 Nov 2022
New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE
24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of ...
Posted by Michael Wonder on 24 Nov 2022
Camurus announces that Braeburn resubmits NDA for Brixadi in the US
23 November 2022 - Camurus today announced that its US licensee Braeburn has resubmitted the new drug application for Brixadi (buprenorphine) ...
Posted by Michael Wonder on 24 Nov 2022
Enhertu approved in Japan for patients with previously treated HER2 positive metastatic breast cancer
24 November 2022 - Approval broadens indication for Enhertu to earlier use in metastatic breast cancer and requirement for confirmatory ...
Posted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...
Posted by Michael Wonder on 24 Nov 2022
Luspatercept for the treatment of patients with anaemia caused by myelodysplastic syndrome
24 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 24 Nov 2022
Luspatercept for the treatment of patients with anaemia caused by beta thalassaemia
24 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...